Wockhardt is the only company in the world to hold QIDP status from the US FDA for six antibiotics - a designation reserved for drugs that address urgent unmet medical needs - and it recently delivered the first Indian-discovered drug to go from lab bench to US approval. Founded in 1967 by Dr. Habil Khorakiwala as a generics business, the company spent the last 25 years pivoting into a science-first enterprise that targets the superbugs the world’s antibiotic pipeline had abandoned, while also building an integrated diabetes biosimilars franchise. The recurring approach is to own the full chain - from basic research and API (active pharmaceutical ingredient) manufacturing all the way to the patient - and to exit businesses, like US generics, that no longer fit that model.
Business segments
Three engines at different stages - a global branded-generics backbone spanning India, the UK and emerging markets, a novel-antibiotics pipeline that has just produced its first approved drug, and an integrated diabetes-biosimilars platform built on in-house manufacturing and patented delivery devices.
1. Pharmaceuticals: the branded-generics backbone that funds the science
A portfolio of over 250 products sold in 40-plus countries, anchored by a top-five position in the UK generics market and a fast-growing India branded business.
- Top-five supplier to the UK’s NHS - Wockhardt has been one of the largest suppliers to the National Health Service for over 20 years, with an 18% covered market share across hospital, pharmacy and export segments, and a portfolio spanning tablets, capsules, injections and liquid medicines.
- India business built on chronic therapies - the domestic branded portfolio focuses on diabetes, orthopedics, pain and regenerative medicine, supported by a field force of over 750 representatives; the company holds market leadership in plain methylcobalamin (a form of vitamin B12).
- Irish foothold with niche leadership - in Ireland, Wockhardt is the sixth-largest generic supplier in both retail and hospital channels, and holds the number-one position in five products including methadone and codeine, backed by a local liquids and creams portfolio.
- Emerging markets through partners - the business reaches Brazil, Thailand, Algeria and Malaysia via strategic distribution partnerships, with the biotech insulin segment and Latin American operations providing the strongest traction.
- Manufacturing across three continents - 11 to 12 plants in India, the UK and Ireland cover solids, injectables, liquids, nasal sprays and complex technologies, including a 612,000-square-foot sterile injectables site in Wrexham, North Wales.
2. Novel Antibiotics: a pipeline of first-in-class drugs for superbugs
Six new chemical entities, each with QIDP status from the US FDA, targeting the resistant Gram-negative and Gram-positive infections that kill over 3.5 million people globally each year - and the lead drug just won US approval.
- Zaynich: the first Indian-discovered drug to reach the US market - approved by the US FDA in May 2026 for complicated urinary tract infections, Zaynich is a first-in-class β-lactam enhancer that kills bacteria by targeting multiple penicillin binding proteins rather than merely inhibiting resistance enzymes; in its pivotal Phase III trial it delivered an 89% composite cure rate versus 68.4% for meropenem, and under compassionate use it has now cured 85 patients with otherwise untreatable infections.
- Miqnaf: the first new macrolide in almost 30 years - launched in India in May 2025, this once-a-day, three-day oral treatment for community-acquired bacterial pneumonia works against pathogens that are over 65% resistant to azithromycin, and showed 96.7% efficacy in Phase III trials.
- Emrok and Emrok O: the only rapidly bactericidal anti-MRSA option - available in both injectable and oral forms, this drug allows patients to start treatment in hospital and finish at home; over 140,000 patients have been treated in India, where it has captured roughly 10% market share and is growing at over 100% year-on-year.
- Odrate: a once-a-day injectable designed to keep patients out of hospital - built on the same Zidebactam enhancer as Zaynich, Odrate is the only once-daily drug in the global antibiotic pipeline designed for outpatient parenteral therapy; its Phase I trial was sponsored and funded by the US National Institutes of Health.
- Foviscu: a potential workhorse replacement for standard hospital antibiotics - positioned as an entry-level empiric treatment for Gram-negative infections, a combined Phase 2/3 clinical trial has been initiated in 324 hospitalized patients, with the Phase 2 portion successfully completed and no serious adverse events reported, and is described by a leading infectious-disease expert as having genuine potential to replace ceftriaxone and piperacillin-tazobactam.
3. Biotechnology: an integrated diabetes-biosimilars franchise with its own delivery devices
A portfolio of human insulin and insulin analogues - from API to finished pen - sold in over 30 emerging markets and growing fast as the global leader exits parts of the business.
- End-to-end in-house manufacturing - the company makes its own drug substance across four API blocks and drug product across two facilities, with in-house bio-assay labs and a clinical pharmacokinetic unit; this vertical integration saves time and cost versus competitors who outsource bio-similarity testing.
- Patented pens, not just drugs - Wockhardt has indigenously designed and globally patented its own insulin delivery devices, holding 23 pen patents worldwide, with second-generation disposable and reusable pens already launched and next-generation devices under development.
- Aspart filing opens a two-player market - a marketing-approval application for Insulin Aspart has been submitted to India’s drug regulator; the Indian Aspart market is worth over INR 260 crore and currently has only two competitors.
- Novo Nordisk’s exit creates a gap - the world’s largest insulin company is discontinuing its disposable pens and cartridges to focus on GLP-1 drugs, opening up a space worth roughly INR 450 crore in India and $157 million in emerging markets; Wockhardt is doubling capacity over the next 24 months and building a new facility to capture it.
Group structure and partners
A family-controlled Indian listed company with 27 subsidiaries, a Swiss-based international hub, and deep partnerships with Serum Institute of Life Sciences, the US NIH, and China’s Jemincare Group.
- Khorakiwala family at the helm - founder Dr. Habil Khorakiwala serves as Chairman, with his children holding the roles of Managing Director, Executive Director and Non-Executive Director.
- Wockhardt Bio AG is the international engine - this Swiss subsidiary, 85.85% owned by the listed parent, is the most significant entity by revenue and the vehicle through which the novel-antibiotics commercialisation is being channelled, including two new US subsidiaries incorporated in Delaware in December 2025.
- Serum Institute partnership for vaccines - a 15-year profit-sharing collaboration (51:49 in Wockhardt’s favour) with Serum Life Sciences UK reserves capacity for 150 million vaccine doses per annum from a new sterile fill-and-finish facility in Wrexham.
- Jemincare deal for Miqnaf in China - Wockhardt has licensed exclusive development and commercialisation rights for nafithromycin in Greater China to Jiangxi Jemincare Group, receiving an upfront payment, milestone payments and royalties on net sales.
- US exit cleaned up via Chapter 7 - the underperforming US generics subsidiaries Morton Grove Pharmaceuticals and Wockhardt USA LLC were placed into voluntary liquidation under Chapter 7 of the US Bankruptcy Code in July 2025, removing a business that lost nearly $8 million in FY 2025 alone.